Clinical Science Core

临床科学核心（核心C） 临床科学核心（CSC;核心C）将是所有D-CFAR临床和 翻译研究活动。核心小组的一个主要目标是提供专门知识和服务， 促进D-CFAR调查人员设计、实施和开展艾滋病毒/艾滋病临床试验。 该核心将由Michael Keefer博士指导，他拥有广泛的行政和临床研究 体验.该核心将通过开发一个 “礼宾团队服务”，借鉴了乌拉圭艾滋病毒/艾滋病主要临床诊所20年的经验 研究项目。虽然财政限制显然限制了“网络式”支持的程度， 我们广泛的专业知识将使我们能够以逐步的方式进行， 提供“以患者为中心”的服务，以满足临床上最迫切的需求。 研究人员在设计、实施和开展研究时面临的问题。“礼宾团队服务” 还将利用D-CFAR和整个UR机构的其他专业知识， 该计划的D-CFAR调查人员可以访问的协调服务菜单。知识 将通过“方案设计”服务提供援助， 与病毒学/免疫学核心（核心D）合作。核心C的第二个重点领域是 创建“生物统计服务”，旨在满足研究者在研究期间确定的需求; D-CFAR应用的战略规划过程（包括国际合作伙伴的需求 在南非;见下文）。第三个重点领域是“专门服务”， 生物数学建模（这是UR的主要机构优势）和临床药理学 服务最后，核心C的活动和服务将建立在不断增长的 乌拉圭回合正在与南非成功的研究同事培养合作。基弗医生的 目前与Glenda Gray博士（U-Witwatersrand [UWj / Perinatal HIV Linda-Gail Bekker博士（开普敦大学/ Desmond Tutu艾滋病毒中心 [DTHC]）通过HVTN运营将构成合作的初步基础。我们的目标是 乌拉圭回合-南非的合作在几年内发展成为基础广泛的机构间合作 来的

CLINICAL SCIENCES CORE (CORE C) The Clinical Sciences Core (CSC; Core C) will be the focal point of all D-CFAR clinical and translational research activities. A major goal for the Core will be to provide expertise and services to facilitate the design, implementation and conduct of HIV/AIDS clinical trials by D-CFAR investigators. The Core will be directed by Dr. Michael Keefer, who has extensive administrative and clinical research experience. The Core will provide support for clinical and translational research by developing a "Protocol Team Service" that draws on the 20 year experience of the major UR HIV/AIDS clinical research programs. While fiscal restraints obviously limit the extent to which a "network-like" support structure can be established, our extensive expertise will allow us to proceed in a step-wise fashion to provide an 'investigator-centered' service that addresses the most pressing needs that clinical researchers face as they design, implement and conduct their studies. The "Protocol Team Service" will also leverage other expertise within the D-CFAR and the UR institution as a whole to present a coordinated menu of services that the program's D-CFAR investigators can access. Intellectual assistance will be provided through a "protocol design" service, and laboratory assays provided in collaboration with the Virology/Immunology Core (Core D). A second area of focus for Core C will be the creation of a "Biostatistical Service" designed to meet investigator needs that were identified during the strategic planning process for this D-CFAR application (including the needs of international partners in South Africa; see below). The third area of emphasis will be on "Specialized Services" - notably biomathematical modeling (which is a major institutional strength at UR) and clinical pharmacology services. Finally, the activities and services of Core C will be designed to build upon the growing collaboration that the UR is nurturing with successful research colleagues in South Africa. Dr. Keefer's current close working relationship with Dr. Glenda Gray (U-Witwatersrand [UWj / Perinatal HIV Research Centre [PHRU]) and Dr. Linda-Gail Bekker (U-Cape Town [UCT] / Desmond Tutu HIV Centre [DTHC]) through HVTN operations will form the initial foundation of the collaboration. It is our goal for the UR-South African collaboration to evolve into a broad-based inter-institutional collaboration in years to come.